<?xml version='1.0' encoding='utf-8'?>
<document id="16611111"><sentence text="Thienopyridines and statins: assessing a potential drug-drug interaction."><entity charOffset="0-15" id="DDI-PubMed.16611111.s1.e0" text="Thienopyridines" /></sentence><sentence text="Clopidogrel and statins are frequently administered in patients with ischemic heart disease or other atherothrombotic manifestations and are effective in the prevention of cardiovascular disease"><entity charOffset="0-11" id="DDI-PubMed.16611111.s2.e0" text="Clopidogrel" /></sentence><sentence text=" The thienopyridine clopidogrel is a pro-drug metabolised in the liver via the cytochrome P450 (CYP) 3A4 system to the active compound which inhibits the P2Y(12) ADP platelet receptor"><entity charOffset="5-31" id="DDI-PubMed.16611111.s3.e0" text="thienopyridine clopidogrel" /></sentence><sentence text=" The assumption exists that the effect of clopidogrel in inhibiting platelet aggregation is attenuated by co-administration of lipophilic statins such as atorvastatin or simvastatin which are metabolised by the CYP3A4 system to inactive substrates"><entity charOffset="42-53" id="DDI-PubMed.16611111.s4.e0" text="clopidogrel" /><entity charOffset="154-166" id="DDI-PubMed.16611111.s4.e1" text="atorvastatin" /><entity charOffset="170-181" id="DDI-PubMed.16611111.s4.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.16611111.s4.e0" e2="DDI-PubMed.16611111.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s4.e0" e2="DDI-PubMed.16611111.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16611111.s4.e0" e2="DDI-PubMed.16611111.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16611111.s4.e1" e2="DDI-PubMed.16611111.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16611111.s4.e1" e2="DDI-PubMed.16611111.s4.e2" /></sentence><sentence text=" Assessing a possible drug-drug interaction ex-vivo, inconclusive studies have been published: In an aggregometer study, a strong and dose-dependent interference between atorvastatin and the inhibitory effect of clopidogrel on platelet function was observed"><entity charOffset="170-182" id="DDI-PubMed.16611111.s5.e0" text="atorvastatin" /><entity charOffset="212-223" id="DDI-PubMed.16611111.s5.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s5.e0" e2="DDI-PubMed.16611111.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s5.e0" e2="DDI-PubMed.16611111.s5.e1" /></sentence><sentence text=" Another study, measuring the effect of clopidogrel by flow cytometry, found a significant attenuation of the clopidogrel effect by lipophilic statins, predominantly in the loading phase"><entity charOffset="40-51" id="DDI-PubMed.16611111.s6.e0" text="clopidogrel" /><entity charOffset="110-121" id="DDI-PubMed.16611111.s6.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s6.e0" e2="DDI-PubMed.16611111.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s6.e0" e2="DDI-PubMed.16611111.s6.e1" /></sentence><sentence text=" In contrast a recent study, which used 600 mg clopidogrel for loading, found no significant interference between various statins and clopidogrel on ADP-induced platelet aggregation and in addition another study revealed no attenuation of the clopidogrel effect despite statin co-medication after 5 weeks"><entity charOffset="47-58" id="DDI-PubMed.16611111.s7.e0" text="clopidogrel" /><entity charOffset="134-145" id="DDI-PubMed.16611111.s7.e1" text="clopidogrel" /><entity charOffset="243-254" id="DDI-PubMed.16611111.s7.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s7.e0" e2="DDI-PubMed.16611111.s7.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s7.e0" e2="DDI-PubMed.16611111.s7.e1" /><pair ddi="false" e1="DDI-PubMed.16611111.s7.e0" e2="DDI-PubMed.16611111.s7.e2" /><pair ddi="false" e1="DDI-PubMed.16611111.s7.e1" e2="DDI-PubMed.16611111.s7.e1" /><pair ddi="false" e1="DDI-PubMed.16611111.s7.e1" e2="DDI-PubMed.16611111.s7.e2" /></sentence><sentence text=" Additionally, retrospective analysis of clinical studies (CREDO-study) or registries (MITRA-PLUS) revealed no significant influence of different statins on the clinical outcome in patients treated with clopidogrel"><entity charOffset="203-214" id="DDI-PubMed.16611111.s8.e0" text="clopidogrel" /></sentence><sentence text=" However, these clinical studies showed a trend towards a diminishing effect of clopidogrel on those treated with cytochrome CYP3A4 metabolised statins"><entity charOffset="80-91" id="DDI-PubMed.16611111.s9.e0" text="clopidogrel" /></sentence><sentence text=" Even more important seems to be the considerable variability in the response of the antiplatelet effect of clopidogrel"><entity charOffset="108-119" id="DDI-PubMed.16611111.s10.e0" text="clopidogrel" /></sentence><sentence text=" A certain percentage of patients apparently do not respond adequately to clopidogrel treatment"><entity charOffset="74-85" id="DDI-PubMed.16611111.s11.e0" text="clopidogrel" /></sentence><sentence text=" This effect of clopidogrel resistance seems to be more important as the potential interference between CYP3A4 metabolized statins and clopidogrel"><entity charOffset="16-27" id="DDI-PubMed.16611111.s12.e0" text="clopidogrel" /><entity charOffset="135-146" id="DDI-PubMed.16611111.s12.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s12.e0" e2="DDI-PubMed.16611111.s12.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s12.e0" e2="DDI-PubMed.16611111.s12.e1" /></sentence><sentence text=" Finally, up until now sufficient evidence has not been gained to prefer hydrophil statins on patients receiving clopidogrel co-medication or when to discontinue the use of statins in clopidogrel treatment"><entity charOffset="113-124" id="DDI-PubMed.16611111.s13.e0" text="clopidogrel" /><entity charOffset="184-195" id="DDI-PubMed.16611111.s13.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s13.e0" e2="DDI-PubMed.16611111.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s13.e0" e2="DDI-PubMed.16611111.s13.e1" /></sentence><sentence text=" Prospective studies are necessary in order to evaluate the magnitude of clopidogrel resistance and the impact of clopidogrel co-medication as well as to redefine antithrombotic therapy for this subgroup"><entity charOffset="73-84" id="DDI-PubMed.16611111.s14.e0" text="clopidogrel" /><entity charOffset="114-125" id="DDI-PubMed.16611111.s14.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.16611111.s14.e0" e2="DDI-PubMed.16611111.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16611111.s14.e0" e2="DDI-PubMed.16611111.s14.e1" /></sentence><sentence text="" /></document>